Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

ClinicalTrials.gov ID: NCT02603120

Public ClinicalTrials.gov record NCT02603120. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects Who Are Virologically Suppressed

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to evaluate the efficacy of switching from a regimen of dolutegravir (DTG) and abacavir/lamivudine (ABC/3TC) or a fixed dose combination (FDC) of abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) to a FDC of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing DTG and ABC/3TC as the FDC ABC/DTG/3TC in virologically suppressed Human Immunodeficiency Virus- 1 (HIV-1) infected adults.

Study identification

NCT ID
NCT02603120
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Gilead Sciences
Industry
Enrollment
567 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 10, 2015
Primary completion
May 8, 2017
Completion
Oct 22, 2019
Last update posted
Nov 11, 2020

2015 – 2019

United States locations

U.S. sites
61
U.S. states
22
U.S. cities
51
Facility City State ZIP Site status
Not listed Phoenix Arizona 85012
Not listed Beverly Hills California 90211
Not listed Los Angeles California 90027
Not listed Los Angeles California 90033
Not listed Los Angeles California 90036
Not listed Los Angeles California 90069
Not listed Oakland California 94602
Not listed Oakland California 94609
Not listed Palm Springs California 92264
Not listed Sacramento California 95187
Not listed Sacramento California 95825
Not listed San Leandro California 94577
Not listed Washington D.C. District of Columbia 20009
Not listed Washington D.C. District of Columbia 20036
Not listed DeLand Florida 32720
Not listed Fort Lauderdale Florida 33308
Not listed Fort Lauderdale Florida 33316
Not listed Ft. Pierce Florida 34982
Not listed Miami Florida 33133
Not listed Miami Beach Florida 33139
Not listed Orlando Florida 32803
Not listed Pensacola Florida 32504
Not listed Tampa Florida 33614
Not listed Vero Beach Florida 32960
Not listed West Palm Beach Florida 33401
Not listed Wilton Manors Florida 33305
Not listed Augusta Georgia 30912
Not listed Decatur Georgia 30033
Not listed Macon Georgia 31201
Not listed Savannah Georgia 31401
Not listed Honolulu Hawaii 96813
Not listed Chicago Illinois 60613
Not listed Chicago Illinois 60657
Not listed Louisville Kentucky 40202
Not listed New Orleans Louisiana 70112
Not listed Boston Massachusetts 02118-2393
Not listed Springfield Massachusetts 01105
Not listed Berkley Michigan 48072
Not listed Detroit Michigan 48202
Not listed Minneapolis Minnesota 55415
Not listed Kansas City Missouri 64111
Not listed St Louis Missouri 63139
Not listed Newark New Jersey 07102
Not listed Santa Fe New Mexico 87505
Not listed Buffalo New York 14215
Not listed New York New York 10011
Not listed The Bronx New York 10467-2490
Not listed Charlotte North Carolina 28207
Not listed Greenville North Carolina 27834
Not listed Huntersville North Carolina 28078
Not listed Cincinnati Ohio 45267-0560
Not listed Philadelphia Pennsylvania 19107
Not listed Columbia South Carolina 29203-6840
Not listed Austin Texas 78705
Not listed Dallas Texas 75219
Not listed Dallas Texas 75246
Not listed Houston Texas 77004
Not listed Houston Texas 77098
Not listed Longview Texas 75605
Not listed Seattle Washington 98104
Not listed Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02603120, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 11, 2020 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02603120 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →